These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8200216)

  • 1. Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia.
    La Vecchia C
    Contraception; 1994 Mar; 49(3):223-30. PubMed ID: 8200216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
    Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
    Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Ye Z; Ray RM
    Contraception; 1995 Jan; 51(1):25-31. PubMed ID: 7750280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Ray RM
    Contraception; 1995 Nov; 52(5):307-12. PubMed ID: 8585888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive cervical cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Noonan L; Whitehead A; Roseman D
    Bull World Health Organ; 1985; 63(3):505-11. PubMed ID: 2931205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Contraception; 1992 Apr; 45(4):299-312. PubMed ID: 1387601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control study of breast cancer and hormonal contraception in Costa Rica.
    Lee NC; Rosero-Bixby L; Oberle MW; Grimaldo C; Whatley AS; Rovira EZ
    J Natl Cancer Inst; 1987 Dec; 79(6):1247-54. PubMed ID: 2961909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Int J Cancer; 1991 Sep; 49(2):182-5. PubMed ID: 1831801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association.
    Herrero R; Brinton LA; Reeves WC; Brenes MM; de Britton RC; Tenorio F; Gaitan E
    Int J Cancer; 1990 Jul; 46(1):5-7. PubMed ID: 2163991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in-situ in women aged 50 years and under.
    Hoyo C; Cousins DS; Bisgrove EZ; Gaines MM; Schwingl PJ; Fortney JA
    West Indian Med J; 2004 Dec; 53(6):406-12. PubMed ID: 15816269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Int J Cancer; 1991 Sep; 49(2):191-5. PubMed ID: 1831803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Noonan L; Whitehead A
    Bull World Health Organ; 1985; 63(3):513-9. PubMed ID: 2931206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Lancet; 1991 Oct; 338(8771):833-8. PubMed ID: 1681212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in cervical cytologic and histologic findings between women using depot-medroxyprogesterone acetate and oral contraceptives.
    Clark MK; Stockdale CK; Railsback L; Nichols S
    J Low Genit Tract Dis; 2011 Jul; 15(3):219-23. PubMed ID: 21716050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Int J Cancer; 1991 Sep; 49(2):186-90. PubMed ID: 1831802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly combined injectable contraceptives and neoplasia.
    Skegg DC
    Contraception; 1994 May; 49(5):435-9. PubMed ID: 8045130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of once-a-month combined injectable contraceptives.
    Sang GW
    Contraception; 1994 Apr; 49(4):361-85. PubMed ID: 8013220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.